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KEY MESSAGES
 26.5% of patients had 1 CVD; 10.5% had 2 CVD diagnoses.
 Each CVD was associated with other CVDs and many other comorbidities.
 In case of CVD, physicians should be alert for another CVD; these patients must be closely and carefully
monitored for other chronic diseases.
ABSTRACT
Background: Comorbidity is a cause of increased mortality, decreased quality of life and
increased use of healthcare services. It is important particularly for physicians and other health-
care providers in primary care settings to evaluate these patients properly. Cardiovascular dis-
eases (CVD) are the most common cause of death from non-communicable diseases worldwide
and are characterized by a high level of comorbidities.
Objectives: To address the distribution of CVDs and comorbidities across sociodemographic
groups and associations between CVDs and comorbidities.
Methods: A cross-sectional study was conducted using data of 67 786 patients. Data were col-
lected by the Registration Network Family Practices (RegistratieNet Huisartspraktijken, RNH).
Comorbidities were analysed using chi-square and logistic regression analyses.
Results: At the time of study, 26.5% of the patients had at least one CVD and 10.5% of patients
had two or more CVD diagnoses. The strongest association within cardiovascular diseases were
between health failure and arrhythmias (OR: 9.20; 95%CI: 7.78–10.89). Coronary artery disease
and hypertension had strong relationship with diabetes (OR: 2.22; 95%CI: 2.02–2.45, OR: 2.22;
95%CI: 2.02–2.45 respectively) and lipid metabolism disorders (OR: 2.04; 95%CI: 1.87–2.23, OR:
2.04; 95%CI: 1.87–2.23, respectively). The strongest associations for cerebrovascular diseases were
with epilepsy (OR: 4.09; 95%CI: 3.29–5.10) and arrhythmias (OR: 2.23; 95%CI: 1.99–2.50).
Conclusion: One out of every four patients suffered from at least one CVD. Having one CVD
increased the risk of another, co-occurring CVD and a higher number of other chronic diseases.
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Introduction
Cardiovascular diseases (CVDs) are the most common
cause of death from non-communicable diseases.
Globally, an estimated 17.5 million people died from
CVDs in 2012, representing 31% of all global deaths [1].
According to the ‘Top 10 leading causes of death by
age groups’ statistics of the Center for Disease Control
(CDC), CVDs are in the top three of most common
causes of death in people older than 35 years [2].
Weiner et al., found that patients with CVD who also
have chronic kidney disease are 35% more vulnerable
to recurrent CVD or mortality compared to CVD patients
without comorbidity [3]. Tripathy et al., found that the
risk of mortality from CVD among patients who have no
history of previous heart attack is higher for patients
with diabetes than for those without diabetes [4].
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It is important for GPs and other healthcare pro-
viders to manage patients with CVD in a way that
takes comorbidity into account [5]. Management of
these patients in primary care settings is important
since patients with comorbidity are characterized by
increased mortality, decreased quality of life, and
increased use of healthcare services compared to
patients without comorbidity [6–8]. In addition, the
occurrence of comorbidity influences medical decision-
making by physicians as regards prevention, treatment
and utilization of services [9], and comorbidity
increases the frequency of visits to general practi-
tioners (GPs) and other medical specialists [10].
Previous studies have established relationships
between CVDs and other chronic conditions, mainly
focusing on specific age groups or chronic disease
types [11–14], but few studies have addressed an
extensive range of chronic disease categories [8,15,16].
The healthcare providers in general practice should be
alert for additional diseases in patients with CVD, and
should monitor these patients closely and spend more
time with them. This can help to prevent comorbidity
or slow down disease progression over time, and
might result in higher quality of life and decreased
mortality [10]. It is against this background that the
present study intended to help primary care providers
to optimize the care for patients with CVD by describ-
ing the relationships between CVDs and comorbidity.
This study aimed to explore the occurrence of
comorbidity among patients with CVD.
Materials and methods
Study design and participants
This cross-sectional, observational study was based on
data from the Registration Network Family Practices
(RegistratieNet Huisartspraktijken, RNH). This network
was developed in the Netherlands in 1988 to establish
a computerized database. Basic sociodemographic
characteristics of patients and all relevant past and
current permanent health problems are recorded sys-
tematically and are updated continuously. Registration
of medical information is part of daily routine.
Registered health problems are added and uploaded
to the RNH database every three months. For the
registration of diseases, the International Classification
of Primary Care (ICPC) is used, applying the criteria of
the International Classification of Health Problems in
Primary Care (ICHPPC-2), or other relevant criteria.
Once a GP accepts inclusion onto the RNH system,
patients are informed about their GP’s participation in
the RNH-system and can opt-out. Sixty-five GPs from
22 practices store information and all of them are
located in the province of Limburg in the Netherlands.
The patient population in the database is representa-
tive for the Dutch population [17].
As of 31 December 2015, 69 953 patients were reg-
istered in the database. Selecting for age (<85 years)
and excluding patients with data errors, 67 786
patients were included in the analysis.
Sociodemographic and lifestyle variables
The RNH database records permanent, serious, chronic
or recurrent problems, together with a limited number
of sociodemographics like age, sex, and living situ-
ation. For our analysis, the age of the patients was
stratified into four age groups; young (0–24), adult
(25–44), middle age (45–64) and older (65–84). In add-
ition, the patients’ living situation was classified into
five categories: living with a family, single, as a couple
without children, living in nursing home or other, such
as commune, and unknown.
Disease groups.The most common CVDs were
selected and clustered into five groups based on
pathophysiological similarities, before relating them to
the chronic non-cardiovascular diseases. The subgroups
of both CVD groups and non-cardiovascular chronic
disease groups are shown in Supplementary Appendix
1 (available online). Only diseases affecting the heart or
arterial blood vessels were included in the CVD groups,
whereas diseases affecting the venous system were
excluded as index diseases but included as comorbid-
ities. Thus, arrhythmias were included as a chronic
comorbidity disease group. In total, nine CVDs are
grouped into five disease groups. These are: (1) acute
myocardial infarction and other/chronic ischaemic
heart disease such as coronary artery disease; (2) heart
failure; (3) uncomplicated hypertension and hyperten-
sion with involvement in target organs; (4) cerebrovas-
cular disease consisting of transient ischaemic attack
and stroke/cerebrovascular accident; and (5) peripheral
artery disease atherosclerosis and other arterial
diseases.
The chronic disease groups were based on the list
previously used by Aarts et al. [12]. However, we made
some modifications to study the relationship between
selected CVDs and additional chronic diseases. A few
diseases (osteoarthritis, rheumatoid arthritis, osteopor-
osis, epilepsy, lipid metabolism disorders, asthma, and
COPD/chronic bronchitis) were analysed separately to
examine the relationship of each disease with CVDs. A
few other disease categories (other diseases of the
nervous system, other chronic respiratory diseases,
chronic skin ulcer) were deleted because of the low
2 C. KENDIR ETAL.
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number of patients in these groups and lack of statis-
tical power.
In the study, CVD was used as the index disease
and an additional disease to CVD is accepted as
comorbidity.
Statistical analysis
The statistical analysis was done using SPSS 22.0 soft-
ware. The relationship between sociodemographics
and having none, one, or two or more CVDs, and the
difference between observed and expected probabil-
ities, were studied using chi-square analysis. A P-value
of less than 5% was considered statistically significant.
The relationship between each CVD and another CVD
or with another chronic comorbid disease was ana-
lysed by logistic regression, involving both crude ana-
lysis and adjustment for age and sex. In these
analyses, age was used as a categorical variable. We
also analysed the relationship between having two or
more CVDs and the numbers of comorbidities (none,
one or two, and more) among patients with CVD,
using logistic regression adjusted for age and sex. The
results are presented as odds ratios with 95% confi-
dence intervals or Pearson chi-square values.
Results
Characteristics of the study population
The mean age of the patients was 45± 21.7 years
with a median age of 48 years; descriptive data of
patients are shown in Table 1. At the time of study,
26.5% of the patients had at least one CVD and
10.5% of patients had two or more CVD diagnoses.
The proportion of patients who had CVD as well as
the number of CVDs per patient increased with
increasing age.
Supplementary Appendix 2 shows the distribution
of other chronic diseases over the different age
groups, sex and living situation. In nearly all chronic
disease groups, the number of cases increased greatly
among persons aged over 45 years. The most common
diagnoses were diseases of the eye, diseases of the
veins, osteoarthritis, mood disorders, asthma and lipid
metabolism disorders. One third of the patients had
more than one non-CVD diagnosis.
Comorbidity with CVDs
Table 2 shows the associations between CVDs and
other CVDs. For all CVD groups, positive and signifi-
cant odds ratios were found for all combinations,
which means that having one CVD always increased
the risk of having another CVD.
Table 3 shows the associations between CVDs and
other chronic diseases. All CVDs showed associations
with many of the comorbidities studied.
Coronary artery diseases had the strongest associ-
ation with arrhythmias (OR: 2.55; 95%CI: 2.30–2.82),
diabetes mellitus (OR: 2.22; 95%CI: 2.02–2.45) and lipid
metabolism disorder (OR: 2.04; 95%CI: 1.87–2.23).
Hypertension showed a strong association with
arrhythmias (OR: 2.05; 95%CI: 2.30–2.82), diabetes mel-
litus (OR: 2.22; 95%CI: 2.02–2.45), and lipid metabolism
disorder (OR: 2.04; 95%CI: 1.87–2.23).
Heart failure showed the strongest association with
arrhythmias (OR: 9.20; 95%CI: 7.78–10.89). In addition,
it showed a strong association with diseases of the
eye (OR: 2.34; 95%CI: 1.98–2.78), pulmonary circulatory
disease (OR: 2.10; 95%CI: 1.54–2.86), rheumatoid arth-
ritis (OR: 2.15; 95%CI: 1.54–2.99), COPD and bronchitis
(OR: 3.27; 95%CI: 2.69–3.97), thyroid disorders (OR:
2.14; 95%CI: 1.64–2.78), diabetes mellitus (OR: 3.16;
95%CI: 2.66–3.75) and gout (OR: 3.11; 95%CI:
2.46–3.93). Alternatively, heart failure showed a nega-
tive association with migraine and headache (OR: 0.57;
95%CI: 0.35–0.93).
Cerebrovascular diseases showed a positive associ-
ation with all chronic comorbidities, the strongest
associations being those with epilepsy (OR: 4.09;
95%CI: 3.29–5.10) and arrhythmias (OR: 2.23; 95%CI:
1.99–2.50).
Peripheral artery diseases showed a strong associ-
ation with peptic ulcer (OR: 2.05; 95%CI: 1.69–2.48),
COPD and bronchitis (OR: 3.06; 95%CI: 2.68–3.48), dia-
betes mellitus (OR: 2.24; 95%CI: 1.99–2.52) and lipid
metabolism disorder (OR: 2.06; 95%CI: 1.86–2.29).
Table 1. Description of the study population (n¼ 67786).
Cardiovascular diseases
None % (n) 1 % (n) 2 % (n) Total % (n)
Age groups
0–24 95.6 (14365) 4.0 (595) 0.4 (66) 100 (15026)
25–44 92.7 (14327) 6.2 (960) 1.1 (166) 100 (15453)
45–64 70.0 (15700) 20.9 (4699) 9.1 (2044) 100 (22443)
65–84 36.5 (5430) 30.7 (4567) 32.7 (4867) 100 (14864)
Sex
Male 72.8 (24293) 15.2 (5059) 12.0 (4011) 100 (33363)
Female 74.2 (25529) 16.7 (5762) 9.1 (3132) 100 (34423)
Living situation
Family 74.3 (26899) 16.1 (5821) 9.6 (3474) 100 (36194)
Single 68.2 (5009) 18.0 (1318) 13.8 (1014) 100 (7341)
Couple 58.9 (4921) 22.5 (1877) 18.7 (1561) 100 (8359)
Other 77.2 (358) 12.3 (57) 10.6 (49) 100 (464)
Unknown 81.9 (12635) 11.3 (1748) 6.8 (1045) 100 (15428)
Total 73.5 (49822) 16.0 (10821) 10.5 (7143) 100 (67786)
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Discussion
Main findings
Our findings show that in a large population of patients
from a primary care registration network (RNH), one out
of every four patients suffered from at least one CVD.
Having one CVD increased the risk of another, co-occur-
ring CVD and a higher number of other chronic dis-
eases. The strongest association was found between
heart failure and coronary artery disease. In addition,
patients with peripheral artery disease were found to
have a more than three-fold increased risk for coronary
artery disease, heart failure and cerebrovascular disease
compared to patients without peripheral artery disease.
Diseases of the eyes, osteoarthritis, mood disorders and
lipid metabolism disorders were the most prevalent
comorbidities, and all showed a positive association
with each of the CVDs.
Comparison with existing literature
This study is a modified replication of the 1997 study
by Landwehr Johan et al. [15], who analysed the
co-occurrence of six CVD groups with 30 chronic
disease groups in the RNH population (n¼ 73 254). We
analysed five CVD groups and 25 chronic disease
groups, using the RNH database as available 19 years
later. Comparing the results of these two studies
shows that the current study found a higher number
of comorbidities with a significant positive association
with CVDs. Furthermore, the associations between
CVDs and comorbidity we found were stronger than
those in the previous study when making the same
adjustments. This might be a result of increased and
improved screening or diagnostics of some diseases
like diabetes mellitus, lipid metabolism disorders or
epilepsy, resulting in earlier treatment with better
results and less comorbidity. The difference could also
be due to some disease groups being analysed separ-
ately in the previous study and grouped together in
our study. However, having more comorbidity com-
pared to the previous study is also a result of aging
population in Europe that has been shown on the
dataset of Eurostat in comparison of years 2005 and
2015 [18].
Previous studies also found that patients with CVD
were at increased risk for comorbidities compared to
patients without such disease [4,19–21]. In our study,
Table 2. Relationship of cardiovascular diseases with other cardiovascular diseases.
Coronary artery diseases Hypertension Heart failure Cerebrovascular diseases Peripheral artery diseases
Adj. OR (95%CI) Adj. OR (95%CI) Adj. OR (95%CI) Adj. OR (95%CI) Adj. OR (95%CI)
Diseases
Peripheral artery disease 3.11 (2.74–3.53) 2.25 (2.03–2.49) 3.64 (2.96–4.47) 3.59 (3.16–4.09) –
Cerebrovascular diseases 1.73 (1.52–1.96) 2.26 (2.07–2.48) 2.25 (1.81–2.78) – a
Heart failure 6.13 (5.14–7.31) 2.06 (1.75–2.43) – a a
Hypertension 1.90 (1.75–2.07) – a a a
Coronary artery disease – a a a a
Additional cardiovascular diseases 2.30 (2.11–2.51) 2.11 (1.98–2.24) 3.44 (2.78–4.25) 2.58 (2.33–2.84) 3.29 (2.94–3.69)
aChanging dependent and independent variables resulted in same odds ratios.
Adj. OR: odds ratios adjusted for age and sex; 95%CI: 95% confidence interval.
Table 3. Relationship between cardiovascular diseases and chronic comorbid diseases.
Coronary artery diseases Hypertension Heart failure Cerebrovascular diseases Peripheral artery diseases
Chronic comorbid diseases Adj. OR (95% CI) Adj. OR (95% CI) Adj. OR (95% CI) Adj. OR (95% CI) Adj. OR (95% CI)
Diseases
All malignancies 1.30 (1.15–1.47) 1.19 (1.10–1.29) 1.55 (1.25–1.92) 1.27 (1.12–1.45) 1.27 (1.10–1.47)
Peptic ulcers 1.41 (1.18–1.68) 1.26 (1.11–1.43) 1.95 (1.46–2.62) 1.60 (1.33–1.94) 2.05 (1.69–2.48)
Diseases of the eye 1.51 (1.37–1.67) 1.68 (1.58–1.79) 2.34 (1.98–2.78) 1.61 (1.45–1.79) 1.82 (1.62–2.04)
Diseases of the ear 1.41 (1.25–1.59) 1.36 (1.25–1.48) 1.61 (1.30–2.00) 1.54 (1.35–1.75) 1.20 (1.03–1.41)
Arrhythmias 2.55 (2.30–2.82) 2.05 (1.90–2.21) 9.20 (7.78–10.89) 2.23 (1.99–2.50) 1.96 (1.72–2.23)
Pulmonary circulatory disease 1.33 (1.09–1.62) 1.30 (1.14–1.48) 2.10 (1.54–2.86) 1.80 (1.48–2.18) 1.74 (1.40–2.16)
Osteoarthritis 1.34 (1.22–1.47) 1.65 (1.56–1.75) 1.45 (1.22–1.72) 1.29 (1.17–1.43) 1.48 (1.32–1.65)
Rheumatoid arthritis 1.33 (1.07–1.65) 1.41 (1.23–1.61) 2.15 (1.54–2.99) 1.65 (1.33–2.03) 1.38 (1.07–1.77)
Mood disorders 1.46 (1.30–1.62) 1.32 (1.23–1.40) 1.53 (1.24–1.89) 1.58 (1.41–1.77) 1.38 (1.21–1.57)
Other mental disorders 1.49 (1.28–1.74) 1.14 (1.04–1.25) 1.68 (1.26–2.25) 1.57 (1.33–1.84) 1.52 (1.28–1.82)
COPD and bronchitis 1.97 (1.74–2.22) 1.34 (1.23–1.46) 3.27 (2.69–3.97) 1.78 (1.56–2.04) 3.06 (2.68–3.48)
Psoriasis 1.42 (1.21–1.67) 1.32 (1.19–1.46) 1.61 (1.19–2.16) 1.34 (1.12–1.60) 1.58 (1.31–1.90)
Thyroid diseases 1.81 (1.54–2.13) 1.42 (1.29–1.57) 2.14 (1.64–2.78) 1.45 (1.23–1.72) 1.46 (1.21–1.76)
Diabetes mellitus 2.22 (2.02–2.45) 3.17 (2.96–3.40) 3.16 (2.66–3.75) 1.68 (1.50–1.87) 2.24 (1.99–2.52)
Lipid metabolism disorder 2.04 (1.87–2.23) 3.53 (3.34–3.74) 1.29 (1.08–1.54) 1.58 (1.43–1.74) 2.06 (1.86–2.29)
Gout 1.53 (1.32–1.77) 3.22 (2.89–3.60) 3.11 (2.46–3.93) 1.61 (1.36–1.91) 1.88 (1.58–2.25)
Adj. OR: odds ratios adjusted for age and sex; 95%CI: 95% confidence interval.
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all CVDs showed a positive association with all malig-
nancies, peptic ulcer, eye diseases, ear diseases,
arrhythmias, pulmonary circulatory diseases, osteoarth-
ritis, rheumatoid arthritis, mood disorders, other men-
tal disorders, COPD and bronchitis, thyroid disorders,
diabetes mellitus, lipid metabolism disorders and gout.
We found a negative association between migraine
and heart failure, which was not described previously,
to our knowledge. Based on the existing literature
[15], we expected a positive association between
migraine and all CVDs, but in our study, the associ-
ation between migraine and CVDs was not significant
for any of the CVD groups. We found a significant
positive association only between migraine and hyper-
tension and cerebrovascular diseases.
Another result of the present study which differed
from previous work regarded the association between
asthma and CVDs. Asthma showed a statistically sig-
nificant positive association only with hypertension,
heart failure and cerebrovascular diseases, not with
other CVDs. In the literature, however, CVDs are the
second most common comorbidities of asthma [22], so
we had expected a positive association between
asthma and each of the CVDs. This might be due to
lack of questioning of the predisposing and associated
factors such as smoking habits, family history and
environmental factors.
Strengths
 The RNH database includes a large number of
patients and a broad spectrum of chronic disease
diagnoses. Its dataset covers a long period, and the
data are reliable.
 The study also included children, young adult
patients, providing data on the whole population
with CVDs and comorbidities, rather than being
limited to the older population, who are known to
have a higher number of comorbidities.
Limitations
 Lack of availability of some sociodemographic data
and risk factors, like body mass index (BMI) and
patients’ smoking behaviour, limited us in adjusting
our findings for potential confounders.
 We did not analyse the data for concordant
(sharing the same pathogenesis or treatment
approach) or discordant (not sharing the same
pathogenesis or treatment approach) morbidity.
Our study thus provides no indication whether
comorbidities were a result of common patho-
logical mechanisms.
Conclusion
GPs and other primary care healthcare providers
should take the results of the present study into
account in making decisions regarding the care for
patients with CVDs and comorbidities. Our findings
have implications for the way healthcare providers
manage and coordinate the care for these patients.
Once a patient has a CVD, the healthcare provider
should be particularly alert for another CVD, and must
closely and carefully monitor these patients for other
chronic diseases. In addition, knowledge of the associ-
ation between CVDs and comorbidities can guide
health promotion workers in developing guidelines for
the management of these patients in primary care.
Our findings also have implications for health legisla-
tors who have to define priorities for future healthcare
planning. We expect that prevention, screening, early
diagnosis and treatment of comorbid conditions in
CVD patients will improve the health outcomes and
quality of life for these patients.
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